Pearland, TX, United States of America

Thiruvengadam Arumugam

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Thiruvengadam Arumugam

Introduction

Thiruvengadam Arumugam, based in Pearland, Texas, is an accomplished inventor dedicated to advancing medical science through his innovative research. He has made significant contributions to the field of cancer treatment, focusing on the development of novel therapeutic antibodies.

Latest Patents

Arumugam holds one patent titled "Blocking monoclonal antibodies to AGR2 and its receptor C4.4A." This patent includes the provision of monoclonal antibodies that recognize, bind to, and block interactions of other molecules with AGR2 and C4.4A. Additionally, it details methods utilizing anti-AGR2 and anti-C4.4A antibodies to treat cancer, showcasing his dedication to finding new ways to combat this prevalent disease.

Career Highlights

Thiruvengadam Arumugam is affiliated with the University of Texas System, a prestigious institution known for its cutting-edge research and contributions to higher education. His work emphasizes the importance of scientific inquiry and innovation in addressing critical health challenges.

Collaborations

Throughout his career, Arumugam has collaborated with esteemed colleagues such as Craig D. Logsdon and Vijaya Ramachandran. These partnerships illustrate the collaborative spirit of research and innovation, which often leads to groundbreaking discoveries in the life sciences.

Conclusion

Thiruvengadam Arumugam is a notable inventor who is making strides in the field of cancer research through his innovative work on monoclonal antibodies. His dedication to developing effective treatments shines through in his patent and collaborative efforts, marking him as an important figure in contemporary medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…